Research article · 30 Nov 2015
Conference abstractPublished 15 Oct 2013
Discovery of novel bicyclic derivatives to stop the growth of Mycobacterium tuberculosis by inhibiting MenA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Tuberculosis (TB) is the second largest infection in number of deathsaround the world. Importantly, about one third of world population has latent tuberculosis. However, HIV-TB is growing fast, especially HIV is stimulating latent TB to form active TB infection. In addition drug resistant TB is also a challenge for researchers. In this order novel drugs are necessary to eradicate TB. Most of the TB drugs were based on inhibiting the process of cell wall and protein synthesis, therefore a novel method is important for drug discovery and development.Interestingly, Bacilli require electron transport chain components and ATP synthesis for survival. The lipoquinones involved in the respiratory chains of bacteria consists of menaquinones and ubiquinones where else; mammals require only ubiquinone, which makes more specific to Bacilli. In relation, menaquinone is an essential component in theelectron transfer process, similarly, MenA is an essential enzyme involved in the synthesis of menaquinone. In addition menaquinones are the major lipoquinones of mycobacteria and other Gram Positive bacteria. Hence MenA promising drug target is explored in determining the inhibitor. While screening and designing inhibitors we observed that bicyclic derivatives showed high coordinating complexes with enzymes in transition state and interrupted the growth of M. Tb. Especially, alkylamino bicyclic complexes showed extensive inhibition towards Mtb. The quantitative structure activity relationship was carried out for the alkyl amino bicyclic complex and tested against Gram Positive bacteria. After optimizing the inhibitorswe observed promising MIC and IC50 values to encounter the infection.
Subjects
ChemistryPharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Research article · 31 May 2015
Development of rifampicin derivatives sensitive to the rpoB mutated Mycobacterium tuberculosis: An insilico approach
Research article · 31 Oct 2016
Insilico Identification of Novel Inhibitors for Shikimate Kinase from Mycobacterium Tuberculosis using Natural and Synthetic Ligands
Conference abstract · 15 Oct 2013
Cluster-based molecular docking study for in silico identification of novel 6-fluoroquinolones as potential inhibitors against Mycobacterium tuberculosis
Research article · 3 May 2019
Synthesis, characterization and in vitro anti Mycobacterium tuberculosis evaluation of some novel phthalimide derivatives
More from this journal
The newest in Medicinal Chemistry.
Brief report · 30 Jun 2026
Covalent Drugs in Medicinal Chemistry: Emerging Opportunities and Ongoing Challenges
Commentary · 29 Dec 2025
Accelerating Drug Discovery: Molecular Docking and Virtual Screening
Opinion · 29 Dec 2025
Pharmacophore Modeling: A Cornerstone of Drug Discovery
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalMedicinal Chemistry
- SubjectChemistry
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Prabagaran Narayanasamy”

